title: I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma.
abstract: Pheochromocytomas and paragangliomas are rare tumors arising from chromaffin cells. Available therapeutic modalities consist of chemotherapy, tyrosine kinase inhibitors, and I-131 metaiodobenzylguanidine (MIBG). I-131 MIBG is taken up via specific receptors and localizes into many but not all pheochromocytomas and paragangliomas. Because these tumors are rare, most therapy studies are retrospective presentations of clinical experience. Numerous retrospective studies and a few prospective studies have shown favorable responses in this disease, including symptomatic, biochemical, and objective responses. In this report, we review the experience of using I-131 MIBG therapy for targeting pheochromocytoma and paragangliomas.
authors.affiliation: Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering, New York, NY; Department of Radiology, Weill Cornell Medical Center, New York, NY. Electronic address: carrasj1@mskcc.org.
authors.forename: Jorge A
authors.initials: JA
authors.lastname: Carrasquillo
authors.affiliation: Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering, New York, NY; Department of Radiology, Weill Cornell Medical Center, New York, NY.
authors.forename: Neeta
authors.initials: N
authors.lastname: Pandit-Taskar
authors.affiliation: Nuclear Medicine, Department of Radiology & Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD.
authors.forename: Clara C
authors.initials: CC
authors.lastname: Chen
mesh_terms: D019797:3-Iodobenzylguanidine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000310:Adrenal Gland Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D010235:Paraganglioma / Q000473:pathology / Q000532:radiotherapy*; D010673:Pheochromocytoma / Q000473:pathology / Q000532:radiotherapy*
chemical_list: D019797:3-Iodobenzylguanidine